Citigroup’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,800
| Closed | -$1.14M | – | 5862 |
|
|
2025
Q1 | $1.14M | Sell |
1,800
-38,800
| -96% | -$26.7M | ﹤0.01% | 3151 |
|
|
2024
Q4 | $28.9M | Sell |
40,600
-400
| -1% | -$336K | 0.02% | 762 |
|
|
2024
Q3 | $43.1M | Buy |
41,000
+400
| +1% | +$445K | 0.03% | 599 |
|
|
2024
Q2 | $42.7M | Buy |
40,600
+4,000
| +11% | +$3.88M | 0.03% | 556 |
|
|
2024
Q1 | $35.2M | Buy |
36,600
+800
| +2% | +$761K | 0.02% | 632 |
|
|
2023
Q4 | $31.4M | Sell |
35,800
-87,400
| -71% | -$72M | 0.02% | 646 |
|
|
2023
Q3 | $101M | Buy |
123,200
+92,800
| +305% | +$72.9M | 0.08% | 229 |
|
|
2023
Q2 | $21.8M | Buy |
30,400
+12,000
| +65% | +$9.25M | 0.01% | 776 |
|
|
2023
Q1 | $15.1M | Buy |
18,400
+14,900
| +426% | +$11.2M | 0.01% | 946 |
|
|
2022
Q4 | $2.53M | Sell |
3,500
-10,000
| -74% | -$7.38M | ﹤0.01% | 1866 |
|
|
2022
Q3 | $9.3M | Buy |
13,500
+10,000
| +286% | +$6.29M | 0.01% | 1181 |
|
|
2022
Q2 | $2.07M | Hold |
3,500
| – | – | ﹤0.01% | 2077 |
|
|
2022
Q1 | $2.44M | Sell |
3,500
-8,800
| -72% | -$5.57M | ﹤0.01% | 2201 |
|
|
2021
Q4 | $7.77M | Sell |
12,300
-18,500
| -60% | -$11.4M | ﹤0.01% | 1545 |
|
|
2021
Q3 | $18.6M | Buy |
30,800
+12,500
| +68% | +$7.76M | 0.01% | 1046 |
|
|
2021
Q2 | $10.2M | Buy |
18,300
+5,000
| +38% | +$2.53M | 0.01% | 1400 |
|
|
2021
Q1 | $6.29M | Sell |
13,300
-48,700
| -79% | -$23.7M | ﹤0.01% | 1638 |
|
|
2020
Q4 | $30M | Buy |
62,000
+23,500
| +61% | +$12.7M | 0.02% | 799 |
|
|
2020
Q3 | $21.6M | Sell |
38,500
-40,200
| -51% | -$24.4M | 0.01% | 862 |
|
|
2020
Q2 | $49.1M | Sell |
78,700
-31,400
| -29% | -$17.8M | 0.04% | 401 |
|
|
2020
Q1 | $53.8M | Buy |
110,100
+60,700
| +123% | +$25M | 0.05% | 330 |
|
|
2019
Q4 | $18.5M | Buy |
49,400
+10,300
| +26% | +$3.47M | 0.01% | 1020 |
|
|
2019
Q3 | $10.8M | Buy |
39,100
+18,700
| +92% | +$5.53M | 0.01% | 1335 |
|
|
2019
Q2 | $6.38M | Sell |
20,400
-2,600
| -11% | -$866K | 0.01% | 1768 |
|
|
2019
Q1 | $9.44M | Sell |
23,000
-33,600
| -59% | -$13.8M | 0.01% | 1306 |
|
|
2018
Q4 | $21.1M | Buy |
56,600
+13,900
| +33% | +$5.09M | 0.02% | 798 |
|
|
2018
Q3 | $17.3M | Sell |
42,700
-23,800
| -36% | -$9.06M | 0.02% | 922 |
|
|
2018
Q2 | $22.9M | Buy |
66,500
+5,700
| +9% | +$1.78M | 0.02% | 727 |
|
|
2018
Q1 | $20.9M | Sell |
60,800
-31,500
| -34% | -$11M | 0.02% | 753 |
|
|
2017
Q4 | $34.7M | Buy |
92,300
+3,900
| +4% | +$1.58M | 0.03% | 573 |
|
|
2017
Q3 | $39.5M | Buy |
88,400
+18,300
| +26% | +$8.71M | 0.03% | 491 |
|
|
2017
Q2 | $34.4M | Buy |
70,100
+22,300
| +47% | +$9.76M | 0.03% | 496 |
|
|
2017
Q1 | $18.5M | Sell |
47,800
-41,200
| -46% | -$15.3M | 0.02% | 777 |
|
|
2016
Q4 | $32.7M | Sell |
89,000
-27,000
| -23% | -$10.3M | 0.03% | 530 |
|
|
2016
Q3 | $46.6M | Sell |
116,000
-11,800
| -9% | -$4.73M | 0.04% | 361 |
|
|
2016
Q2 | $44.6M | Buy |
127,800
+78,700
| +160% | +$30.3M | 0.05% | 352 |
|
|
2016
Q1 | $17.7M | Buy |
49,100
+23,100
| +89% | +$9.52M | 0.02% | 662 |
|
|
2015
Q4 | $14.1M | Buy |
26,000
+100
| +0.4% | +$54.2K | 0.01% | 927 |
|
|
2015
Q3 | $12M | Buy |
25,900
+9,500
| +58% | +$5.1M | 0.01% | 1011 |
|
|
2015
Q2 | $8.37M | Buy |
16,400
+9,800
| +148% | +$4.78M | 0.01% | 1332 |
|
|
2015
Q1 | $2.98M | Buy |
6,600
+5,400
| +450% | +$2.29M | ﹤0.01% | 2153 |
|
|
2014
Q4 | $492K | Sell |
1,200
-3,300
| -73% | -$1.3M | ﹤0.01% | 3904 |
|
|
2014
Q3 | $1.62M | Buy |
+4,500
| New | +$1.51M | ﹤0.01% | 2706 |
|
|
2014
Q2 | – | Sell |
-74,800
| Closed | -$22.5M | – | 7281 |
|
|
2014
Q1 | $22.5M | Buy |
74,800
+54,800
| +274% | +$16.9M | 0.02% | 652 |
|
|
2013
Q4 | $5.5M | Hold |
20,000
| – | – | 0.01% | 1727 |
|
|
2013
Q3 | $6.26M | Sell |
20,000
-19,400
| -49% | -$5.1M | 0.01% | 1555 |
|
|
2013
Q2 | $8.86M | Buy |
+39,400
| New | +$9.17M | 0.01% | 1163 |
|
Other funds holding REGN
VCM
N
Citigroup's REGN Position: Q1 2026 in Review
Citigroup reduced its Regeneron Pharmaceuticals (REGN) stake by 25% in Q1 2026, selling an estimated $46.4M and leaving 184,691 shares worth $143M. The position accounts for 0.06% of the portfolio, ranked #292.
Citigroup first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $189M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Citigroup held 184,691 shares of Regeneron Pharmaceuticals worth $143M as of Q1 2026.
- Citigroup sold 60,644 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $46.4M.
- Regeneron Pharmaceuticals made up 0.06% of Citigroup's portfolio in Q1 2026, its #292 holding.
- Citigroup first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Regeneron Pharmaceuticals position peaked at $189M in Q4 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.